[go: up one dir, main page]

AR006119A1 - Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos - Google Patents

Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos

Info

Publication number
AR006119A1
AR006119A1 ARP970100888A ARP970100888A AR006119A1 AR 006119 A1 AR006119 A1 AR 006119A1 AR P970100888 A ARP970100888 A AR P970100888A AR P970100888 A ARP970100888 A AR P970100888A AR 006119 A1 AR006119 A1 AR 006119A1
Authority
AR
Argentina
Prior art keywords
compounds
quinoxalinas
quinoxalinadionas
procedure
manufacture
Prior art date
Application number
ARP970100888A
Other languages
English (en)
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of AR006119A1 publication Critical patent/AR006119A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)

Abstract

Compuestos de quinoxalinadiona de la fórmula (I) y las sales farmacéuticamente aceptables de los mismos, en donde R, R1 y R2 son como sedefinen en la memoria. También se proporcionan composiciones que contienen dichos compuestos,los usos de los mismos e intermediarios de quinoxalinausados en su síntesis. Los compuestos son útiles como antagonistas de receptores NMDA para el tratamiento de trastornos neurodegenerativos agudos ytrastornos neurológicos.
ARP970100888A 1996-03-09 1997-03-05 Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos AR006119A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9605027.3A GB9605027D0 (en) 1996-03-09 1996-03-09 Quinoxalinediones

Publications (1)

Publication Number Publication Date
AR006119A1 true AR006119A1 (es) 1999-08-11

Family

ID=10790134

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100888A AR006119A1 (es) 1996-03-09 1997-03-05 Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos

Country Status (42)

Country Link
US (1) US6376490B1 (es)
EP (1) EP0885212B1 (es)
JP (1) JP3110467B2 (es)
KR (1) KR100288099B1 (es)
CN (1) CN1103770C (es)
AP (1) AP767A (es)
AR (1) AR006119A1 (es)
AT (1) ATE208773T1 (es)
AU (1) AU717972B2 (es)
BG (1) BG63340B1 (es)
BR (1) BR9707851A (es)
CA (1) CA2248366C (es)
CO (1) CO4770976A1 (es)
CZ (1) CZ292792B6 (es)
DE (1) DE69708269T2 (es)
DK (1) DK0885212T3 (es)
DZ (1) DZ2188A1 (es)
EA (1) EA001730B1 (es)
ES (1) ES2163742T3 (es)
GB (1) GB9605027D0 (es)
HN (1) HN1998000034A (es)
HR (1) HRP970132A2 (es)
HU (1) HUP9900975A3 (es)
ID (1) ID18112A (es)
IL (1) IL125491A (es)
IS (1) IS4811A (es)
MA (1) MA26422A1 (es)
NO (1) NO984058L (es)
NZ (1) NZ331060A (es)
OA (1) OA10850A (es)
PE (2) PE43398A1 (es)
PL (1) PL329032A1 (es)
PT (1) PT885212E (es)
SI (1) SI0885212T1 (es)
SK (1) SK283467B6 (es)
TN (1) TNSN97044A1 (es)
TR (1) TR199801782T2 (es)
TW (1) TW454004B (es)
UY (1) UY24482A1 (es)
WO (1) WO1997032873A1 (es)
YU (2) YU39698A (es)
ZA (1) ZA971987B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1121403C (zh) * 1997-02-27 2003-09-17 辉瑞大药厂 喹喔啉二酮
AP982A (en) 1997-02-27 2001-07-16 Pfizer Quinoxalinediones.
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
DE10005150A1 (de) * 2000-02-07 2001-08-09 Merck Patent Gmbh Verfahren zur Herstellung von 5-Arylnicotinaldehyden
PL359340A1 (en) * 2000-05-19 2004-08-23 Triazole derivatives
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2005006945A2 (en) * 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
MY145368A (en) * 2004-01-13 2012-01-31 Nissan Chemical Ind Ltd Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
US7799894B2 (en) 2004-02-06 2010-09-21 Yamaguchi University Electrode for energy storage device and process for producing the same
JP2007223901A (ja) * 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
US20060211739A1 (en) * 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
CA2686816A1 (en) 2007-01-16 2008-07-24 The Johns Hopkins University Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
CN101679383B (zh) 2007-05-17 2014-10-29 株式会社半导体能源研究所 三唑衍生物,和使用三唑衍生物的发光元件、发光器件和电子器件
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
JP2016507537A (ja) * 2013-02-07 2016-03-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 置換アセチレン誘導体およびmGluR4の正のアロステリックモジュレーターとしてのそれらの使用
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
CN111548320B (zh) * 2019-10-09 2023-03-24 贵州大学 一类1,3,4-噁二唑酰肼类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0556393B1 (en) * 1990-11-06 2000-07-26 Yamanouchi Pharmaceutical Co. Ltd. Fused pyrazine derivative
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
CN1121403C (zh) * 1997-02-27 2003-09-17 辉瑞大药厂 喹喔啉二酮

Also Published As

Publication number Publication date
US6376490B1 (en) 2002-04-23
NZ331060A (en) 2000-01-28
JP3110467B2 (ja) 2000-11-20
BR9707851A (pt) 1999-07-27
DZ2188A1 (fr) 2002-12-02
CN1213369A (zh) 1999-04-07
AP767A (en) 1999-09-29
SK283467B6 (sk) 2003-08-05
TR199801782T2 (xx) 1998-12-21
IL125491A (en) 2003-07-06
PL329032A1 (en) 1999-03-01
AU717972B2 (en) 2000-04-06
SK121498A3 (en) 2000-10-09
CN1103770C (zh) 2003-03-26
ATE208773T1 (de) 2001-11-15
UY24482A1 (es) 2000-09-29
YU41199A (sh) 2001-09-28
YU39698A (sh) 1999-03-04
JPH11506123A (ja) 1999-06-02
EA199800702A1 (ru) 1999-04-29
NO984058D0 (no) 1998-09-03
HUP9900975A3 (en) 2001-12-28
PE43398A1 (es) 1998-08-29
GB9605027D0 (en) 1996-05-08
EP0885212A1 (en) 1998-12-23
AU2023197A (en) 1997-09-22
DE69708269D1 (de) 2001-12-20
KR19990087614A (ko) 1999-12-27
ZA971987B (en) 1998-09-07
BG102760A (en) 1999-09-30
NO984058L (no) 1998-11-06
CA2248366A1 (en) 1997-09-12
PE58199A1 (es) 1999-06-11
PT885212E (pt) 2002-02-28
ID18112A (id) 1998-03-05
EA001730B1 (ru) 2001-08-27
BG63340B1 (bg) 2001-10-31
WO1997032873A1 (en) 1997-09-12
HN1998000034A (es) 1999-02-09
HRP970132A2 (en) 1998-06-30
IS4811A (is) 1998-07-27
CZ292792B6 (cs) 2003-12-17
CO4770976A1 (es) 1999-04-30
KR100288099B1 (ko) 2001-05-02
DE69708269T2 (de) 2002-07-25
HUP9900975A2 (hu) 1999-07-28
SI0885212T1 (en) 2002-02-28
IL125491A0 (en) 1999-03-12
DK0885212T3 (da) 2002-03-25
AP9700947A0 (en) 1997-04-30
TW454004B (en) 2001-09-11
EP0885212B1 (en) 2001-11-14
MA26422A1 (fr) 2004-12-20
TNSN97044A1 (fr) 2005-03-15
OA10850A (en) 2001-08-16
ES2163742T3 (es) 2002-02-01
CZ286498A3 (cs) 1999-07-14
CA2248366C (en) 2002-06-04

Similar Documents

Publication Publication Date Title
AR006119A1 (es) Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos
ES2159738T3 (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
ES2161290T3 (es) Derivados de quinazolina.
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
ES542320A0 (es) Un procedimiento para la preparacion de derivados de la 2 pirimidinil 1 piperazina
AR005420A1 (es) Compuestos derivados de piperazinas y piperidinas con efecto analgésico, composiciones farmacéuticas que los contienen, uso de los mismos para la fabricación de un medicamento y un proceso para la preparación de dichos compuestos.
ES2158814B1 (es) Derivados de pirrolidina antagonistas del receptor ccr-3
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
ES2168487T3 (es) Derivados de n-heteroaril-piridinasulfonamida y su uso como antagonistas de la endotelina.
SV1998000029A (es) Compuestos de pirazina ref. pg3186
MX9207382A (es) Nuevos compuestos que tienen actividad terapeutica intermediarios para su preparacion, proceso para obtencion de tales compuestos y formulacion farmaceutica que los contiene.
GT199900146A (es) Derivados de 4,4-biarilpiperidina.
MX9300786A (es) Compuestos hipolipidaemicos.
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
ECSP045347A (es) "derivados de acil-4-carboxifenilurea, procedimientos para su preparacion y su uso"
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
UY27023A1 (es) Derivados de fenil cetonas sustituidas como antagonistas de ip
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9301197A (es) Derivados de indol.
MX9300616A (es) Compuestos antagonistas del receptor 5-hidroxitriptamina, proceso para su prepararcion y composicion farmaceutica que los contiene
ES2142030T3 (es) Nuevos compuestos espiro-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2148458T3 (es) Derivados de fenil-4-tiazoles sustituidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2149504T3 (es) Imidazo(1,2-a)quinoxalin-4-aminas activas como antagonistas de la adenosina, procedimiento para su preparacion y composiciones farmaceuticas de las mismas.